Cancer Family
Thymus Neoplasm
CI-CAN-00000366Explore in graph →
Non-malignant104 active trials1 approved drugs1 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000366Explore in graph →
Clinical trials
283 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03517488 | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors(DUET-2) | completed | Phase 1 | 150 | Xencor, Inc.INDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT01272817 | Nonmyeloablative Allogeneic Transplant(Mini-allo) | completed | N/A | 36 | Scripps HealthOTHER | 1 | Nov 23, 2022 | clinicaltrials |
| NCT05001113 |
| Surgery for Masaoka-Koga I-II Thymoma |
| completed |
| N/A |
| 101 |
| Shanghai Zhongshan HospitalOTHER |
| 1 |
| Sep 19, 2022 |
| clinicaltrials |
| NCT05446935 | Intrathoracic Chemotherapy for TETs With Pleural Spread or Recurrence(CHOICE) | unknown | N/A | 37 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02049047 | Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Chemotherapy(ONC-2010-001) | completed | Phase 2 | 41 | Armando Santoro, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02307500 | Regorafenib in Patients With Metastatic Solid Tumors Who Have Progressed After Standard Therapy(RESOUND) | completed | Phase 2 | 82 | Istituto Clinico HumanitasOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT02706405 | JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 24, 2022 | clinicaltrials |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04371458 | Thymectomy With and Without Povidone-iodine Pleural Lavage in Stage IVA Thymic Malignancies | withdrawn | Phase 1 / Phase 2 | 0 | Yale UniversityOTHER | 0 | Jul 25, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT05407649 | Abscopal Effect of Radiotherapy in Combination With rhGM-CSF for Advanced Thymic Epithelial Tumours | unknown | Phase 2 | 60 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05262582 | Comparison of Single Port and Two Ports Robotic Assisted Thoracic Surgery for Thymectomy(RATS) | unknown | N/A | 60 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT04844086 | RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies | terminated | Phase 1 | 2 | Eden BioCell Ltd.INDUSTRY | 1 | May 18, 2022 | clinicaltrials |
| NCT02220855 | A Study of BKM120 (Buparlisib) in Relapsed or Refractory Thymomas | completed | Phase 2 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT02859415 | Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Apr 5, 2022 | clinicaltrials |
| NCT05208853 | An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma | unknown | Early Phase 1 | 9 | Zhejiang UniversityOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT03663764 | Hypofractionated Chemoradiotherapy and Thymosin α1 in Unresectable or Recurrent Thymic Epithelial Tumor | unknown | Phase 2 | 57 | Sun Yat-sen UniversityOTHER | 1 | Dec 10, 2021 | clinicaltrials |
| NCT05061784 | Routine Transcervical Thymectomy in MEN-1 Patients | completed | — | 7 | National University Health System, SingaporeOTHER | 1 | Sep 30, 2021 | clinicaltrials |
| NCT01953692 | A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013) | completed | Phase 1 | 197 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 4, 2021 | clinicaltrials |
| NCT03449173 | Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial)(Style) | unknown | Phase 2 | 56 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Jun 9, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT03613272 | The Curative Effect of Extended Thymectomy Performed Through Subxiphoid-right VATS Approach With Elevation of Sternum | unknown | N/A | 200 | Jiang FanOTHER | 1 | May 7, 2021 | clinicaltrials |
| NCT04824950 | Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)(CAMIL) | recruiting | N/A | 87 | Centre Henri BecquerelOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT04705129 | Zanubrutinib Combined With Tislelizumab in the Treatment of r/r PMBCL and EBV+ DLBCL | unknown | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04822077 | Study on Proton Radiotherapy of Thymic Malignancies(PROTHYM) | recruiting | N/A | 40 | Ass. Prof. Jan NymanNETWORK | 1 | Mar 30, 2021 | clinicaltrials |
| NCT03858582 | neoadjuvant_thymic Epithelial Tumor | unknown | Phase 2 | 40 | Samsung Medical CenterOTHER | 1 | Mar 22, 2021 | clinicaltrials |
| NCT04614818 | A Multi-center, Retrospective Analysis of Clinical Character, Outcome and Prognosis of Lymphoepithelioma-like Carcinoma | unknown | — | 700 | Sun Yat-sen UniversityOTHER | 1 | Nov 4, 2020 | clinicaltrials |
| NCT02420691 | Ribociclib in Treating Patients With Advanced Neuroendocrine Tumors of Foregut Origin | completed | Phase 2 | 21 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT04554524 | Chemotherapy Combined With Pembrolizumab in Treating Patients With Thymoma and Thymic Carcinoma | unknown | Phase 4 | 40 | Tang-Du HospitalOTHER | 1 | Oct 28, 2020 | clinicaltrials |
| NCT04503538 | Telemedicine for Early Detection of Cytokine Release Syndrome and Neurotoxicity | withdrawn | N/A | 0 | Wake Forest University Health SciencesOTHER | 0 | Oct 23, 2020 | clinicaltrials |
| NCT04600947 | Study of LP002 for the Treatment of Patients With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma | unknown | Phase 2 | 69 | Taizhou HoudeAoke Biomedical Co., Ltd.INDUSTRY | 1 | Oct 23, 2020 | clinicaltrials |
| NCT04577495 | Prognostic Factors in Patients Submitted to Surgical Treatment for Thymoma | completed | — | 50 | IRCCS San RaffaeleOTHER | 0 | Oct 8, 2020 | clinicaltrials |
| NCT04522687 | Influence of Radiotherapy and Chemotherapy in the Value of Peripheral Blood Lymphocyte Subsets Among Thoracic Cancer | recruiting | — | 500 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 21, 2020 | clinicaltrials |
| NCT04517539 | Abscopal Effect of SBRT in Combination With rhGM-CSF and INF-α 2b for Metastatic Thymic Epithelial Tumors | unknown | Phase 2 | 65 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT02014805 | Postoperative Conformal Radiotherapy for Stage II-III B Type Thymoma | unknown | Phase 3 | 210 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2020 | clinicaltrials |
| NCT01102192 | The Role of the Thymus in Myasthenia Gravis | completed | — | 20 | Charite University, Berlin, GermanyOTHER | 1 | Jul 10, 2020 | clinicaltrials |
| NCT02607631 | A Study of Pembrolizumab for Patients With Thymic Epithelial Tumor | completed | Phase 2 | 33 | Samsung Medical CenterOTHER | 0 | Jul 9, 2020 | clinicaltrials |
| NCT00921739 | Esophageal Sparing Intensity-modulated Radiation Therapy (IMRT) for Locally-Advanced Thoracic Malignancies(ESIMRT) | completed | Phase 1 | 24 | Duke UniversityOTHER | 1 | Apr 2, 2020 | clinicaltrials |
| NCT01143545 | Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2020 | clinicaltrials |
| NCT02636556 | Chemoradiotherapy for Limited Advanced Unresectable Thymic Epithelial Tumors | completed | N/A | 56 | Fudan UniversityOTHER | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02364076 | Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma | unknown | Phase 2 | 45 | Georgetown UniversityOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT01258868 | Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas | terminated | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | Dec 3, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT00198133 | Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma | completed | Phase 2 | 27 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jul 22, 2019 | clinicaltrials |
| NCT02747732 | Study of Ibrutinib in Combination With Bendamustine and Rituximab for Patients With Relapsed/Refractory Aggressive BCL | unknown | Phase 2 | 72 | Meirav Kedmi MDOTHER_GOV | 1 | Apr 23, 2019 | clinicaltrials |
| NCT01364727 | A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies | completed | Phase 2 | 33 | Heather WakeleeOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT01011439 | Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma | terminated | Phase 2 | 72 | Tiziana Life Sciences LTDINDUSTRY | 3 | Feb 6, 2019 | clinicaltrials |
| NCT01301391 | Study Of Oral PHA-848125AC In Patients With Malignant Thymoma Previously Treated With Multiple Lines Of Chemotherapy | terminated | Phase 2 | 30 | Tiziana Life Sciences LTDINDUSTRY | 2 | Feb 6, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Dec 1, 2022source: clinicaltrials